University status and response to COVID-19
Last updated 18th January 2022
In light of the ongoing high rates of COVID-19 nationally, the continuation of the government’s ‘Plan B’ measures, and the latest guidance for higher education providers issued by the Department for Education, the University has agreed the following measures.
- Health measures: Face coverings are essential for reducing the spread of COVID-19 and should be worn by all staff and students when moving around University buildings. Members of staff conducting teaching are not required to wear face coverings, to support education delivery. Social distancing is not formally required. However, staff and students are expected to respect each other’s space, using the experience of the last two years.
- Working arrangements: Staff who are able to work from home are expected to continue doing so where possible. However, the University is fully open for teaching and research, and buildings remain open and should be accessible to all staff. As such, staff are expected to work on site to support in-person teaching, research and wider University operations where necessary.
Please refer to the University of Oxford Health page for updated health guidance.
We have also included some extra information in the latest health campaign communications pack.
The University is acting on advice from sources including the Foreign and Commonwealth Office, World Health Organization, the NHS and Public Health England. Our own academic experts in infectious diseases and other relevant subjects are involved in our response to coronavirus.
The University moved to Level 2 of the University’s Business Continuity Planning (BCP) framework on Monday 6 September 2021.
The move to BCP 2 removed most COVID-19 restrictions that were previously in place at the University. It brings the University in line with Step 4 of the UK Government’s Roadmap, allowing for in-person learning and assessment wherever possible, a return to working on-site for all staff, and increased public access to University and college facilities.
Podcast: Meet our researchers
25 January 2022
A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.
25 January 2022
A third booster dose of either the ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), AD26.COV2-S (Janssen) or CoronaVac (SinoVac) coronavirus vaccine induce a significant increase in antibody levels in those who have previously received two doses of CoronaVac. The strongest responses were seen with mixed schedules, including against the Delta and Omicron variants of concern.
The role of circadian clock pathways in viral replication
McKeating J. et al, (2022), Springer Seminars in Immunopathology
Doxycycline Alters the Porcine Renal Proteome and Degradome during Hypothermic Machine Perfusion
van Leeuwen L. et al, (2022), Current Issues in Molecular Biology, 44, 559 - 577
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences
Lee JY. et al, (2022), eLife, 11
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
Peng Y. et al, (2022), Nature Immunology, 23, 50 - 61
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
Mould AW. et al, (2022), CNS Drugs, 36, 1 - 16
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124